Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 May 2019: Trial registered, NCT03953898
  2. 4 Aug 2020: Trial started, NCT03953898

The trials

NCT03953898: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

State
Under way
Phase
Phase 2
People
14 taking part
Started
4 Aug 2020
Primary completion
16 Jan 2024
Arms
Treatment (olaparib)
Results
Posted on the registry
  1. 17 May 2019: Trial registered
  2. 4 Aug 2020: Trial started
  3. 30 Mar 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.